Skip to main content

Table 1 Demographic data of the study groups

From: Assessment of glypican-3 immune expression in ameloblastoma, ameloblastic fibroma, ameloblastic carcinoma (pilot study)

Demographic data

Number of cases

Precentage

DF

AF

AB

ABC

DF (%)

AF (%)

AB (%)

ABC (%)

Site

        

Ant. Max

3

0

0

0

30

0

0

0

Post. Max

0

0

0

0

0

0

0

0

Crossing Midline Max

0

0

0

1

0

0

0

10

Ant. Mand

1

0

0

0

10

0

0

0

Post. Mand

6

9

9

8

60

90

90

80

Crossing Midline Mand

0

1

1

1

0

10

10

10

Age

        

< 20 y

5

0

0

0

50

0

0

0

20–40 y

5

4

6

2

50

40

60

20

40–60 y

0

0

1

4

0

0

10

40

> 60 y

0

0

3

4

0

0

30

40

Gender

        

Male

7

8

6

10

70

80

60

100

Female

3

2

4

0

30

20

40

0